APA (7th ed.) Citation

Provenzano, M., Jongs, N., Vart, P., Stefánsson, B. V., Chertow, G. M., Langkilde, A. M., . . . Heerspink, H. J. (2022, March). The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. Kidney International Reports.

Chicago Style (17th ed.) Citation

Provenzano, Michele, et al. "The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists." Kidney International Reports Mar. 2022.

MLA (9th ed.) Citation

Provenzano, Michele, et al. "The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists." Kidney International Reports, Mar. 2022.